Almirall to ensure business continuity of all drugs essential for patients

Almirall, S.A. (ALM) has announced today that despite the current situation generated by the spread of COVID19, and in order to ensure the well-being of its patients, it will continue to produce all essential products. The Company has also increased production capabilities for specific medicines, such as paracetamol, which address symptoms of patients affected by COVID-19. The Company has also triggered an action plan which includes a wide range of measures to respond to the COVID-19 pandemic and help mitigate its adverse effects, and to support the healthcare professionals fighting at the forefront of this crisis. These measures include:

• Donation of Blastoactiva and Balneum topical creams in Spain to help healthcare professionals reduce dry and damaged skin caused by masks, repeated handwashing and the use of sanitizers.
• Donation of Balneum topical cream in the United Kingdom.
• Partial repurposing of production facilities in Germany, to manufacture antibacterial gels.

Last week Almirall donated protective equipment for frontline healthcare workers, including masks, gloves and coats, among other items, to several institutions in Spain. In addition, the Company has announced further donations of medical supplies and personal protective equipment for frontline healthcare workers at Sant Joan Despi Moisès Broggi Hospital and Martorell Hospital, in order to assist and offer support to those professionals. Almirall’s donation will provide more than 11,000 health products for each hospital, from technical gloves, white coats and Tyvek suits to rigid-frame safety glasses and CRITICUM medical provisions.

Almirall and the Leitat Foundation will also work together to develop 3D printed respirators for hospitals and intensive care units in the face of the current health emergency.

Almirall is working on leading and coordinating a global effort to support countries in the prevention, detection and response to the pandemic.

Almirall’s focus is on all those people who have been directly and indirectly affected by this unprecedented health crisis. At Almirall, we are deploying all our talents and efforts to help our patients, healthcare professionals and partners during this crisis, and we will continue to do so until this difficult situation is over.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel better. We support healthcare professionals in their continuous improvements, providing our innovative solutions where they are needed. The company was founded over 75 years ago and has its headquarters in Barcelona. It is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key source of value creation for society thanks to its commitment to its principal shareholders and its decision to help others by understanding their challenges and using science to provide solutions for real life. Total Revenues in 2019 were more than 900 million euros. Almirall has c. 1,800 employees.

For more information, please visit almirall.com